Welcome to our dedicated page for Currenc Group news (Ticker: CURR), a resource for investors and traders seeking the latest updates and insights on Currenc Group stock.
Currenc Group Inc. reports developments in its fintech business, including AI tools for financial institutions and digital remittance services associated with Tranglo and WalletKu. Company updates commonly cover processing activity, remittance revenue, airtime-transfer exposure, operating results, and cost management.
News also includes governance and capital-structure matters for CURR ordinary shares, material agreements, shareholder meeting items, Nasdaq listing-compliance notices, and disclosures tied to the tokenization of ordinary shares. The company is described in its public updates as a Cayman Islands exempted company with securities listed on Nasdaq.
COFEPRIS, Mexico's FDA equivalent, has approved CURE Pharmaceutical's products for manufacture and sale in Mexico. This includes the innovative CUREform™ oral thin film (OTF) delivery system for various wellness products, such as CUREfilm Blue™ (sildenafil for erectile dysfunction), Vitamin D3, sugar-free electrolytes, and a melatonin sleep aid. CURE is in discussions with major distributors in Mexico and Latin America, aiming to expand its reach in the growing health and wellness market. This collaboration with Milagro Pharmaceuticals is expected to enhance CURE's production capabilities.
CURE Pharmaceutical Holdings (OTCQB: CURR) has announced a strategic partnership with Northern Response International to distribute the Seratopical Revolution® skin care line in Canada. This collaboration enables CURE to expand its market presence and brand portfolio internationally. The Seratopical line features plant-based formulations and a proprietary delivery system, endorsed by global icon Nicole Kidman. Northern Response will leverage its extensive distribution channels to promote this masstige brand, enhancing CURE’s reach in the lucrative beauty sector.
CURE Pharmaceutical Holding Corp. (OTC: CURR) announced the upcoming issuance of U.S. Patent No. 11,179,331 for its product CUREfilm Blue™, an oral soluble film containing sildenafil citrate, aimed at treating erectile dysfunction (ED). This innovative drug delivery method utilizes CURE's proprietary CUREfilm™ technology, enhancing patient experience with discreet and convenient administration. The erectile dysfunction drug market is projected to reach approximately USD$6.6 billion by 2025, with significant growth expected for sildenafil.
CURE Pharmaceutical Holding Corp. (OTC: CURR) reported a remarkable 700% revenue increase to $2.1 million for Q2 2021, with gross profit rising 676% to $1.31 million. The net loss decreased significantly to $3.27 million from a loss of $13.47 million year-over-year. Key developments include CVS's upcoming launch of the Seratopical Revolution skincare line, ISO 9001 certification for its facility, successful initial clinical trials of CUREfilm Blue™, and a partnership with Biopharmaceutical Research Company to create cannabis-based medical products for Veterans.
CURE Pharmaceutical (OTC: CURR) announced that its skincare line, Seratopical Revolution, will be available at CVS starting Fall 2021. This partnership positions CURR for expansive market reach, targeting diverse customer needs with its innovative P3P complex, which enhances product efficacy without drying effects. CEO Nancy Duitch highlighted the brand's competitive edge through effective delivery systems and attractive packaging, alongside actress Nicole Kidman as a global ambassador. This development signifies an important milestone for CURR's growth strategy in the beauty industry.
CURE Pharmaceutical Holding Corp. (OTC: CURR) announced that Chief Business Officer Jonathan Berlent will present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17 at 7:00 a.m. EST. Berlent expressed pride in developing the company's psychedelic-based clinical pipeline, emphasizing the therapeutic potential of psychedelics for mental health disorders. The presentation will be accessible online for 90 days post-event. CURE is a leader in innovative drug delivery systems, operating from a state-of-the-art facility.
CURE Pharmaceutical Holding Corp. (OTC: CURR) has launched Seratopical Revolution, a new line of anti-aging beauty products developed in collaboration with global brand ambassador Nicole Kidman. The product line features 11 plant-based items designed to hydrate and rejuvenate skin, utilizing a proprietary delivery system that enhances absorption. Products are made in the U.S. and are affordably priced. The line includes items such as Loving Hands Essential Oil and Indulgence Brown Sugar Scrub, aiming to merge nature and science for effective skincare.
CURE Pharmaceutical Holding Corp. (OTC: CURR) will hold a webcast on May 27, 2021, at 5 p.m. EDT for its investors. CEO Rob Davidson and Nancy Duitch, CEO of The Sera Labs, will discuss the company's future positioning and current achievements. Shareholders are encouraged to submit questions before the event. The company operates a 25,000 sq. ft. FDA-registered manufacturing facility and is known for its CUREform™ drug delivery platform, which enhances drug efficacy and safety.
CURE Pharmaceutical (OTC: CURR) reported a significant Q1 2021 performance, with total revenue soaring over 400% year-on-year to $1.5 million. The company received FDA approval for its Investigational New Drug application for CUREfilm Blue™, targeting erectile dysfunction. Additionally, CURE is advancing clinical development of delivery vehicles for psychedelic compounds. A new line of Nutri-Strips™ vitamins was launched via its Sera Labs subsidiary. CURE also secured a $2.3 million payment from a resolved contract dispute in April 2021.
Summary not available.